Dicerna Pharmaceuticals, Inc. (DRNA) News
Filter DRNA News Items
DRNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DRNA News Highlights
- DRNA's 30 day story count now stands at 28.
- Over the past 29 days, the trend for DRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- LAW, ACT and ASPC are the most mentioned tickers in articles about DRNA.
Latest DRNA News From Around the Web
Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionLEXINGTON, Mass., December 28, 2021--Novo Nordisk today announced that the acquisition of Dicerna, announced on 18 November 2021, has been completed. |
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire DicernaLEXINGTON, Mass., December 25, 2021--Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna |
MainStay VP Wellington Small Cap Portfolio Buys iShares Russell 2000 Growth ETF, United Natural ...Investment company MainStay VP Wellington Small Cap Portfolio (Current Portfolio) buys iShares Russell 2000 Growth ETF, United Natural Foods Inc, Mimecast, Insperity Inc, Chesapeake Energy Corp, sells Ollie's Bargain Outlet Holdings Inc, Apellis Pharmaceuticals Inc, Children's Place Inc, Hostess Brands Inc, Boston Beer Co Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, MainStay VP Wellington Small Cap Portfolio. |
Sumitomo Mitsui Trust Holdings Inc. Trims Stock Position in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)Sumitomo Mitsui Trust Holdings Inc. lessened its position in shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 94.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,901 shares of the biopharmaceutical companys stock after selling 432,596 shares during the quarter. Sumitomo Mitsui Trust Holdings [] |
-$0.44 EPS Expected for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) This QuarterEquities analysts forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will report earnings of ($0.44) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Dicerna Pharmaceuticals earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.99). Dicerna Pharmaceuticals reported earnings per share of ($0.49) during the same quarter last [] |
What Direction Does Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) Analysts Think The Company Will Take?The trading price of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) floating lower at last check on Wednesday, December 15, trading at $37.91, 0.00% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy |
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Receives Average Rating of Hold from AnalystsShares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) have been assigned an average recommendation of Hold from the twelve ratings firms that are covering the company, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokers that [] |
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Receives $31.19 Consensus Price Target from BrokeragesShares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) have been given an average recommendation of Hold by the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Ten analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have [] |
DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNAFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dicerna Pharmaceuticals, Inc. (NasdaqGS: DRNA) to Novo Nordisk A/S (NYSE: NVO). Under the terms of the proposed transaction, shareholders of Dicerna will receive $38.25 in cash for each share of Dicerna that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration |
Hedge Funds Are Selling Dicerna Pharmaceuticals Inc (DRNA)No summary available. |